The company remains in a pre-commercial phase with virtually no product revenue, while R&D expenses reached a significant quarterly peak of $409.9 million in 2025Q2.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 6.93K | 10.4K | 10.4K | 10.4K | 10.4K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | -6.93K | -10.4K | -10.4K | -10.4K | -10.4K |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | 33.34% | 0% | 0% | 0% | - |
| Operating Expenses | 6M | 6.84M | 9.13M | 14.41M | 13.82M | 7.7M | 11.83M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.09B | 5.73B | 7.36B | 11.2M | 7.61M | 5.58M | 5.36M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 911.85M | 1.11B | 1.78B | 3.21M | 5.41M | 2.12M | 6.47M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | -4M | -6.84B | -9.13B | 0 | 809.67K | 0 | 0 |
| Operating Income | 2.14B | -6.84M | -9.14B | -14.42M | -13.83M | -7.7M | -11.83M |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 99.93% | -63258.83% | -4.25% | -79.55% | 34.89% | - |
| EBITDA | -24.34M | -25.29M | -9.14B | -14.41M | -13.82M | -7.69M | -11.82M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | -183.98% | 99.72% | -63304.51% | -4.25% | -79.66% | 34.92% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 6.93K | 10.4K | 10.4K | 10.4K | 10.4K |
| EBIT | -24.34M | -25.29M | -9.15B | -107.75M | -14.44M | -7.26M | -12.17M |
| Net Interest Income | -526.16K | -513.21K | -269.86K | 457 | -427.11K | -820.54K | -515.93K |
| Interest Income | 0 | 0 | 0 | 457 | 428 | 821 | 516 |
| Interest Expense | 526.16K | 513.21K | 269.86K | 0 | 427.54K | 821.37K | 516.45K |
| Other Income/Expense | 92.91M | -18.96M | -283.35M | -93.33M | -1.03M | -379.79K | -850.11K |
| Pretax Income | 2.23B | -25.8M | -9.42B | -107.75M | -14.87M | -8.08M | -12.68M |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | -851.66K | -851.66K | -6.75M | -9.46M | -745.05K | 0 | 0 |
| Effective Tax Rate % | -0.04% | 3.3% | 0.07% | 8.78% | 5.01% | 0% | 0% |
| Net Income | -1.82B | -24.95B | -9.41B | -98.3M | -14.05M | -8.08M | -12.68M |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | -20435.42% | -165.07% | -9476.43% | -599.75% | -73.77% | 36.26% | - |
| Net Income (Continuing) | -24.49M | -24.95M | -9.41B | -98.3M | -14.12M | -8.08M | -12.68M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.22 | -4.18 | -8.48 | -1089.66 | -930.25 | -173.66 | -272.45 |
| EPS Growth % | 57.28% | 50.71% | 99.22% | -17.14% | -435.67% | 36.26% | - |
| EPS (Basic) | - | -4.18 | -8.48 | -1089.66 | -930.25 | -173.66 | -272.45 |
| Diluted Shares Outstanding | 8.1B | 5.96B | 1.11M | 97.5K | 25.95K | 46.55K | 46.55K |
| Basic Shares Outstanding | 8.1B | 5.96B | 1.11M | 97.5K | 25.95K | 46.55K | 46.55K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Binary clinical trial failure
As indicated by the company's historical financial filings, ZyVersa Therapeutics currently generates virtually no product revenue, with the most recent quarterly data showing a complete absence of top-line growth, underscoring the firm's status as a pre-commercial entity entirely dependent on external capital for its ongoing operations.
The lack of consistent revenue streams highlights the company's reliance on future clinical milestones rather than current commercial activity. Investors should monitor the absence of top-line momentum as a primary indicator that the firm remains in a high-risk, early-stage development phase.
Based on reported financial statements, the company's cost structure is dominated by significant R&D and SG&A outlays, with R&D expenses reaching as high as $409.9 million in 2025Q2, reflecting the heavy capital requirements necessary to advance its pipeline of renal and inflammatory therapeutic candidates.
The volatility in quarterly expense reporting suggests that clinical trial milestones and administrative scaling are driving significant cash outflows. This cost profile appears to be structurally disconnected from any revenue generation, necessitating constant scrutiny of the firm's remaining operational runway.
According to recent SEC filings, ZyVersa consistently records substantial stock-based compensation, including a peak of $257.4 million in 2024Q3, which significantly obscures the underlying cash burn and complicates the assessment of true operational efficiency for a company that currently lacks any meaningful commercial revenue.
The high levels of non-cash compensation suggest that management is utilizing equity to preserve cash, which may lead to significant shareholder dilution over time. Analysts should adjust for these non-cash items to better understand the actual cash-based burn rate required to sustain the current clinical development timeline.
While the company reports a cash position of approximately $101.8 million, the historical income statement data reveals aggressive quarterly spending patterns that suggest the current capital reserves may be depleted rapidly if clinical trial costs continue to scale at the rates observed in recent fiscal periods.
The disparity between the reported cash balance and the high quarterly burn rate warrants further investigation into the firm's ability to reach critical clinical inflection points without further dilutive financing. Investors should remain cautious regarding the potential for future capital raises that could significantly impact existing equity holders.
Quick answers to the most common questions about buying ZVSA stock.
For fiscal year 2025, ZyVersa Therapeutics, Inc. (ZVSA) reported total revenue of $0.0M.
ZyVersa Therapeutics, Inc. (ZVSA) reported a net loss of $24.95B for the fiscal year ending 2025.